Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$11.41MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mary T. Szela
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 102
- Beta
- 0.44
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.37
Financials
Revenue
$11.41M+344.5%Net Income
$-9.19MEBITDA
$-7.42MFree Cash Flow
$-16.83MEPS (diluted)
$-0.16Shares Outstanding (diluted)
58.30M+90.8%Operating Expenses
$19.71MCash & Debt
$46.29MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $45.15M | $-39.23M | $-1.84 |
| 2024 | $29.43M | $-33.23M | $-1.25 |
| 2023 | $18.51M | $-59.36M | $-2.23 |
| 2022 | $12.40M | $-47.19M | $-1.59 |
| 2021 | $8.40M | $-28.84M | $-0.92 |
| 2020 | $0.00 | $-31.83M | $-0.02 |
Valuation
TLSIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-40.00%Social Signal Score
Mentions (3)
- Newsbenzinga.com·12d ago·Negative
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support The U.S. Food and Drug Administration (FDA) on Wednesday granted 510(k) clearance for TriSalus Life Sciences Inc.'s (NASDAQ:TLSI) TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery (PEDD) portfolio.
View source ↗ - Newsbusinesswire.com·13d ago·Negative
…ing Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TriNav® Advance, the newest add…
View source ↗ - Newsmarketbeat.com·49d ago·Neutral
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference TriSalus Life Sciences NASDAQ: TLSI outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity's Global Growth Conference, with management emphasizing the company's pressure-enabled delivery technology for solid-tumor treatments.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.14 per share
Typical surprise -61.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.16 vs $-0.15miss
- Tue, May 12$-0.33 vs $-0.16miss
- Thu, Mar 5$-0.21 vs $-0.13miss
- Thu, Nov 13$-0.96 vs $-0.17miss
- Tue, Aug 12$-0.27 vs $-0.22miss
- Thu, May 15$-0.33 vs $-0.20miss
Estimates and results for TLSI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TLSI officers and directors.
- Bought
- $3.6m
- Sold
- $185k
12 trades
17 trades
- Marshak Richardsold
- Wahlstrom Matsbought
- Stansky Michael Pbought
- Stansky Michael Pbought
- Szela Mary Tbought
- Patience Davidbought
- Gordon Gary B.bought
- Szela Mary Tsold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TLSI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.